Chugai Pharmaceutical Co., Ltd. (CHGCF) は上場企業です ヘルスケア セクターの 製薬 業界で事業展開. 本社所在地は Chuo, 日本. 現CEOは Osamu Okuda.
CHGCF を有する IPO日 2012-08-03, 5,026 名の正社員, に上場 Other OTC, 時価総額 $90.63B.
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacture, and sale of medicines globally. The company maintains a diverse portfolio spanning oncology, immunology, hematology, ophthalmology, and other therapeutic areas, with established products including Tecentriq, Herceptin, Avastin, Rituxan, and Tamiflu. As a subsidiary of Roche Holding Ltd., Chugai leverages strategic alliances within the Roche Group and conducts collaborative research with academic institutions to advance its pipeline of development candidates. Founded in 1925 and headquartered in Chuo, Japan, the company continues to expand its international presence across multiple disease indications.
